Companies / Switzerland
Roche Offers US$44bn For Remaining Genentech Shares
July 2008 | Company News AlertIn a deal that could blow the rest of 2008's pharmaceutical acquisitions out of the water, Swiss drugmaker Roche has offered to buy the remaining shares US biotechnology giant Genentech for US$43.7bn. Roche - which currently owns a majority 55.9% share in the US firm - offered US$89 per share, an 8.8% premium on closing
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
